-+ 0.00%
-+ 0.00%
-+ 0.00%
D2 Solutions Unifies Multi-Site Compliance Operations to Support BirdiRx's National Expansion
Share
Listen to the news

Six-month implementation deployed D2's scalable regulatory framework, achieved three major pharmacy accreditations and established a foundation for growth

SAINT CHARLES, Mo., Oct. 14, 2026 /PRNewswire/ -- D2 Solutions, a healthcare consulting and technology company focused on improving patient access to specialty therapies, announced a successful implementation with BirdiRx, a mail-order and specialty pharmacy that processes more than 1 million prescriptions annually. Through the engagement, D2 established a unified regulatory framework for BirdiRx following a period of significant growth for the pharmacy.

Find D2 at d2rx.com

As specialty pharmacies expand operations and support increasingly complex therapies, maintaining consistent compliance processes across teams and locations becomes a significant challenge.

Following a series of acquisitions that brought together pharmacy locations in Arizona, Michigan and Ohio, D2 Solutions worked with BirdiRx to create a consistent compliance framework across multiple facilities while preparing to expand its specialty pharmacy capabilities. D2 Solutions provided the regulatory workflows and tailored technology needed to unify the pharmacy's growing operations.

"BirdiRx needed a compliance framework that could evolve alongside their specialty pharmacy operations," said Mitch Lamb, PharmD, Senior Director of Regulatory Operations and Services at D2 Solutions. "By combining our technology and regulatory expertise, we helped create a foundation that enabled them to streamline compliance across three states and secure several major accreditations in just six months."

During the implementation, D2 Solutions deployed a customized suite of its proprietary technologies to drive key compliance functions for BirdiRx, including:

  • AccredComply™: Supported BirdiRx's efforts to achieve three major pharmacy accreditations simultaneously: URAC, NABP and ACHC.
  • RegComply™: Provided a flexible platform to manage regulatory updates, alerts and compliance tasks, replacing legacy tools that lacked customization.
  • ContractHub™ and IncidentHub™: Delivered customized solutions for healthcare contract management and HIPAA privacy incident tracking.
  • Fair Market Value (FMV) Tool: Helped standardize service pricing processes to support compliance with anti-kickback regulations.

The BirdiRx case study highlights D2 Solutions' specialty pharmacy technology and advisory capabilities, providing a new example of the company's work across the specialty pharmacy ecosystem. D2 Solutions has continued to expand these capabilities through the recent acquisition of ProModRx and ongoing enhancements to its UltraTouch® patient services platform.

To learn about D2 Solutions' consulting services and technology solutions, visit d2rx.com.

About D2 Solutions

D2 Solutions is a healthcare and pharma commercialization partner focused on accelerating patient access to specialty therapies. By combining strategic advisory services with proprietary technology, D2 Solutions works to reduce friction between manufacturers, pharmacies and payers. From streamlining market access and prior authorization to supporting regulatory compliance and accreditation, the D2 Solutions platform is designed to optimize the specialty drug lifecycle and help patients access the therapies they need. Learn more at d2rx.com.

Media Contact

PANBlast for D2 Solutions

d2solutions@panblastpr.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/d2-solutions-unifies-multi-site-compliance-operations-to-support-birdirxs-national-expansion-302903255.html

SOURCE D2 Solutions

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending